Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 vs Chemotherapy in Recurrent or Metastatic Urothelial Carcinoma
NCT06857175Phase 3Active, not recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Mar 2025
- Primary completion
- Jun 2027
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in urothelial carcinoma (UC) (2 arms), sponsored by Biokin Pharmaceutical. Primary endpoints: Progression-Free Survival at 24 months and Overall Survival at 24 months. Started Mar 2025; status: active, not recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT06857175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06857175.